Compare LCII & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | CELC |
|---|---|---|
| Founded | 1956 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | LCII | CELC |
|---|---|---|
| Price | $123.30 | $113.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $124.57 | $107.88 |
| AVG Volume (30 Days) | 224.0K | ★ 647.6K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | ★ 35.18 | N/A |
| EPS | ★ 7.57 | N/A |
| Revenue | ★ $4,122,017,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $4.64 | $706.83 |
| P/E Ratio | $15.87 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $72.31 | $7.58 |
| 52 Week High | $159.66 | $120.32 |
| Indicator | LCII | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 53.58 |
| Support Level | $118.33 | $99.38 |
| Resistance Level | $151.85 | $117.27 |
| Average True Range (ATR) | 3.52 | 6.34 |
| MACD | 0.54 | -0.25 |
| Stochastic Oscillator | 60.19 | 68.66 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.